ArticleInternational urology and nephrology2015
Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer.
Article in International urology and nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies.Epidemiology and health · 2022Pooled it
- Diabetes Mellitus and Obesity as Risk Factors for Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A comprehensive review.Asian journal of urology · 2026Review
- Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer.Cancer medicine · 2023Article
- Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor.Frontiers in oncology · 2023Article
- No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression.PloS one · 2020Article
- Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions.Bladder cancer (Amsterdam, Netherlands) · 2020Article
- Article
- Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience.International urology and nephrology · 2019Article
- An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.World journal of urology · 2019Article
- The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer.Translational andrology and urology · 2018Article
- Optimal body mass index cut-point for predicting recurrence-free survival in patients with non-muscle-invasive urothelial carcinoma of bladder.Oncology letters · 2018Article
- Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.Bladder cancer (Amsterdam, Netherlands) · 2018Article
- The association between metabolic syndrome and bladder cancer susceptibility and prognosis: an updated comprehensive evidence synthesis of 95 observational studies involving 97,795,299 subjects.Cancer management and research · 2018Article
- AACR Cancer Progress Report 2015.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of body mass on recurrence and progression in patients with Ta, T1 urothelial bladder cancer.
methodsData from 469 patients with Ta, T1 bladder cancer who were treated with transurethral resection of bladder tumor at our center during 2006-2014 were retrospectively studied. According to body mass index (BMI), patients were divided into three groups: normal weight (BMI < 24 kg/m(2)), overweight (24 kg/m(2) ≤ BMI < 28 kg/m(2)) and obesity (BMI ≥ 28 kg/m(2)). Clinicopathologic features were compared across groups. Kaplan-Meier curves and Cox proportional hazards regression analyses were employed to assess the association between body mass and oncologic outcomes.
resultsCompared with patients with normal weight, overweight and obese counterparts showed significantly shorter recurrence-free or progression-free survival. In multivariate analyses, being overweight was an independent factor for recurrence and obesity was for both recurrence and progression. The presence of diabetes mellitus (DM) was not a strong risk factor for the entire cohort, while it became a significant predictor for both recurrence and progression in the subgroup of overweight and obese patients.
conclusionExcessive body mass seems to act as independent risk factors for worse oncologic outcomes of Ta, T1 bladder cancer. Further studies should be carried out to elucidate the exact impact of obesity, DM or even other metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.